SEC Form 4 · accession 0001209191-18-034160
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian K Beeler
Officer — EVP, General Counsel
Period of report
May 25, 2018
Accepted (ET)
May 30, 2018 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 25, 2018 | M | 48,000 | $2.40 | A | 110,524 | D | |
| Ordinary SharesF1 | May 25, 2018 | S | 17,931 | $16.11 | D | 92,593 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.40 | May 25, 2018 | M | 48,000 | D | — | Jan 1, 2023 | Ordinary Shares | 48,000 | 0 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.145 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F225% of the shares subject to the option vested and became exercisable on the first anniversary of the date of grant (1/2/2013), and the remaining shares vested in 36 equal monthly installments thereafter.